| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FNMOL.2016.00071 |
| P8608 | Fatcat ID | release_3ktokkhq3zg6lppvnvdejhyyt4 |
| P932 | PMC publication ID | 4981605 |
| P698 | PubMed publication ID | 27570505 |
| P50 | author | Cecilia Giulivi | Q30511277 |
| P2093 | author name string | Flora Tassone | |
| Randi Hagerman | |||
| Eleonora Napoli | |||
| Julian Halmai | |||
| P2860 | cites work | HMDB: the Human Metabolome Database | Q23039065 |
| Molecular markers of early Parkinson's disease based on gene expression in blood | Q24292810 | ||
| Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity | Q24523292 | ||
| Effect of pyrithiamine treatment and subsequent thiamine rehabilitation on regional cerebral amino acids and thiamine-dependent enzymes | Q69368178 | ||
| Tricarboxylic acid cycle intermediates in human muscle at rest and during prolonged cycling | Q73281266 | ||
| Anaplerotic processes in human skeletal muscle during brief dynamic exercise | Q73653980 | ||
| Mass spectrometry-based metabolomics: accelerating the characterization of discriminating signals by combining statistical correlations and ultrahigh resolution | Q81361410 | ||
| Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome | Q24567980 | ||
| HMDB 3.0--The Human Metabolome Database in 2013 | Q24595162 | ||
| Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 | ||
| HMDB: a knowledgebase for the human metabolome | Q24655295 | ||
| The Chemical Translation Service--a web-based tool to improve standardization of metabolomic reports | Q27062596 | ||
| PubChem Substance and Compound databases | Q27942588 | ||
| Leptin-regulated endocannabinoids are involved in maintaining food intake | Q28211969 | ||
| Anandamide may mediate sleep induction | Q28248481 | ||
| An energy budget for signaling in the grey matter of the brain | Q29616192 | ||
| Premutation in the Fragile X Mental Retardation 1 (FMR1) Gene Affects Maternal Zn-milk and Perinatal Brain Bioenergetics and Scaffolding | Q30008925 | ||
| Developmental trends in auditory processing can provide early predictions of language acquisition in young infants | Q30442243 | ||
| Metabolomics by numbers: acquiring and understanding global metabolite data | Q30925430 | ||
| Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines | Q31118037 | ||
| Metabolomic applications to neuroscience: more challenges than chances? | Q31122053 | ||
| Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome | Q33570563 | ||
| Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. | Q33645739 | ||
| Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome | Q33650175 | ||
| Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome | Q33775794 | ||
| Statistical integration of 1H NMR and MRS data from different biofluids and tissues enhances recovery of biological information from individuals with HIV-1 infection | Q33796091 | ||
| The metabolic cost of neural information | Q33858019 | ||
| The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. | Q33901895 | ||
| Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates | Q33905067 | ||
| A missense mutation in human fatty acid amide hydrolase associated with problem drug use. | Q34032872 | ||
| Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. | Q34146206 | ||
| Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. | Q34146987 | ||
| Fragile X and autism: Intertwined at the molecular level leading to targeted treatments | Q34198650 | ||
| Phenylethylamine and schizophrenia | Q34322059 | ||
| Potential therapeutic use of the ketogenic diet in autism spectrum disorders | Q34431317 | ||
| Diagnosis and management of mitochondrial diseases | Q34516793 | ||
| Discovery of metabolomics biomarkers for early detection of nephrotoxicity | Q46043673 | ||
| Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis | Q46574227 | ||
| Region-selective alterations of glucose oxidation and amino acid synthesis in the thiamine-deficient rat brain: a re-evaluation using 1H/13C nuclear magnetic resonance spectroscopy | Q46646115 | ||
| Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. | Q46666276 | ||
| Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study | Q46827956 | ||
| A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease | Q47401613 | ||
| Depletion of striatal beta-phenylethylamine following dopamine but not 5-HT denervation | Q48295367 | ||
| Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. | Q48383261 | ||
| Cognitive impairment in a 65-year-old male with the fragile X-associated tremor-ataxia syndrome (FXTAS). | Q48427447 | ||
| Mitochondrial CB₁ receptors regulate neuronal energy metabolism. | Q48629492 | ||
| Effect of sertraline on regional metabolic rate in patients with affective disorder. | Q48823191 | ||
| Action of beta-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. | Q49113210 | ||
| Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. | Q50278365 | ||
| Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. | Q50278933 | ||
| Decreased cerebrospinal fluid levels of beta-phenylethylamine in patients with Rett syndrome. | Q50312834 | ||
| Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. | Q51894749 | ||
| Urinary phenyl acetate: a diagnostic test for depression? | Q52095254 | ||
| Depression and cerebrospinal fluid citrate | Q52102787 | ||
| Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures. | Q52303845 | ||
| Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? | Q53188799 | ||
| Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. | Q53341924 | ||
| Biochemical abnormalities in Pearson syndrome. | Q53612700 | ||
| Immune-mediated disorders among women carriers of fragile X premutation alleles. | Q55637365 | ||
| Phenylethylamine (PEA) and phenylacetic acid (PAA) in the urine of chronic schizophrenic patients and controls | Q57266292 | ||
| A second fatty acid amide hydrolase with variable distribution among placental mammals | Q34570802 | ||
| Respiratory chain defects in the mitochondria of cultured skin fibroblasts from three patients with lacticacidemia | Q34577359 | ||
| Metabolomics: building on a century of biochemistry to guide human health | Q34591242 | ||
| Chronic exposure to light reverses the effect of maternal separation on proteins in the prefrontal cortex | Q34864441 | ||
| Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome | Q35035766 | ||
| Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome | Q35090105 | ||
| MetaboAnalyst 3.0--making metabolomics more meaningful | Q35610559 | ||
| Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. | Q35786397 | ||
| Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. | Q35909841 | ||
| Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. | Q36026897 | ||
| Mitochondrial Citrate Transporter-dependent Metabolic Signature in the 22q11.2 Deletion Syndrome | Q36281669 | ||
| Decreased beta-phenylethylamine in CSF in Parkinson's disease | Q36317491 | ||
| Young adult male carriers of the fragile X premutation exhibit genetically modulated impairments in visuospatial tasks controlled for psychomotor speed | Q36423826 | ||
| The role of the endocannabinoid system in the control of energy homeostasis. | Q36434442 | ||
| KEGG as a reference resource for gene and protein annotation | Q36434599 | ||
| Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity | Q36546326 | ||
| Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model | Q36588189 | ||
| Metabolic phenotyping and systems biology approaches to understanding neurological disorders | Q36903783 | ||
| Metabolomic analysis and signatures in motor neuron disease | Q36908588 | ||
| Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency. | Q36946491 | ||
| Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. | Q37191378 | ||
| Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome | Q37580522 | ||
| Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. | Q37663133 | ||
| Metabolomics for early detection of drug-induced kidney injury: review of the current status | Q37810166 | ||
| Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission | Q37935452 | ||
| Quality control for plant metabolomics: reporting MSI-compliant studies | Q38502318 | ||
| Warburg effect linked to cognitive-executive deficits in FMR1 premutation | Q39661355 | ||
| Analysis of the adult human plasma metabolome | Q40107287 | ||
| The trace amines and their acidic metabolites in depression--an overview | Q40718373 | ||
| Altered Bioenergetics in Primary Dermal Fibroblasts from Adult Carriers of the FMR1 Premutation Before the Onset of the Neurodegenerative Disease Fragile X-Associated Tremor/Ataxia Syndrome | Q41637163 | ||
| Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. | Q43625342 | ||
| Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo | Q44028862 | ||
| Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system | Q44265419 | ||
| Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation | Q44521568 | ||
| Differential effects of the sleep-inducing lipid oleamide and cannabinoids on the induction of long-term potentiation in the CA1 neurons of the rat hippocampus in vitro | Q44722232 | ||
| Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine | Q45160359 | ||
| Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features | Q45270211 | ||
| Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects | Q45302800 | ||
| Brain structure in asymptomatic FMR1 premutation carriers at risk for fragile X-associated tremor/ataxia syndrome. | Q45981668 | ||
| P921 | main subject | biomarker | Q864574 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 71 | |
| P577 | publication date | 2016-08-12 | |
| P1433 | published in | Frontiers in Molecular Neuroscience | Q27721913 |
| P1476 | title | Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers | |
| P478 | volume | 9 |
| Q60311366 | Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study |
| Q59335598 | Fragile X-Associated Neuropsychiatric Disorders (FXAND) |
| Q46091324 | Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation. |
| Q91947146 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort |
Search more.